Fr. 69.00

Deprenyl, Past and Future

Anglais · Livre de poche

Expédition généralement dans un délai de 1 à 2 semaines (titre imprimé sur commande)

Description

En savoir plus

Expert clinicians and basic scientists with a special interest in Parkinson's disease review the current state of science and clinical therapeutics of the disease. Therefore these articles represent an authorative review of the current state of knowledge regarding preclinical course and symptomatology, subtypes with their impact on the pathology, genetic alterations, novel mechanisms of neuronal cell death, diagnostic tools and old and novel therapeutic approaches with respect to neuroprotection and neuroregeneration in Parkinson's disease. Particular emphasis has been placed on a novel antiparkinsonian drug called budipine with various modes of action also influencing altered non dopaminergic systems in Parkinson's disease. It is evident, that many questions on the cause, course and treatment of Parkinson's disease are still unanswered and therefore the ideal way to treat a parkinsonian patient remains to be defined.

Table des matières

New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease.- New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.- Early diagnosis in Parkinson's disease - limitation of biochemical markers and instrumental methods.- The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in ( )-deprenyl research.- ( )-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.- Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research.- Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.- 8The clinical potential of Deprenyl in neurologic and psychiatric disorders.- Pharmacology and neuroprotective properties of rasagiline.- Potential of neurotrophic factors in therapy of Parkinson's disease.

A propos de l'auteur

Peter Kraus hat Mitte der Fünfziger Jahre des 20. Jahrhunderts den Rock'n Roll nach Deutschland gebracht

Détails du produit

Collaboration P. Kraus (Editeur), Pete Kraus (Editeur), Peter Kraus (Editeur), W. Kuhn (Editeur), Wilfried Kuhn (Editeur), H. Przuntek (Editeur), Horst Przuntek (Editeur)
Edition Springer, Wien
 
Langues Anglais
Format d'édition Livre de poche
Sortie 01.01.1996
 
EAN 9783211828915
ISBN 978-3-211-82891-5
Pages 117
Poids 366 g
Illustrations IX, 117 p.
Thèmes Journal of Neural Transmission
Journal of Neural Transmission
Journal of Neural Transmission. Supplementa
Catégorie Sciences naturelles, médecine, informatique, technique > Médecine > Spécialités non cliniques

Commentaires des clients

Aucune analyse n'a été rédigée sur cet article pour le moment. Sois le premier à donner ton avis et aide les autres utilisateurs à prendre leur décision d'achat.

Écris un commentaire

Super ou nul ? Donne ton propre avis.

Pour les messages à CeDe.ch, veuillez utiliser le formulaire de contact.

Il faut impérativement remplir les champs de saisie marqués d'une *.

En soumettant ce formulaire, tu acceptes notre déclaration de protection des données.